InMed Pharmaceuticals (INM) Restructuring Costs (2022 - 2024)

InMed Pharmaceuticals has reported Restructuring Costs for 3 years, with the latest figure at $104969.0 in Q2 2024.

• For the quarter ending Q2 2024, Restructuring Costs rose 229.36% year-over-year to $104969.0; the trailing twelve-month figure through Jun 2024 stood at $43726.0 (changed N/A YoY), and the FY2024 full-year result was $162200.0, up 187.55% from the prior year.
• Restructuring Costs for Q2 2024 stood at $104969.0, up from $9768.0 in the prior quarter.
• The five-year high for Restructuring Costs was $104969.0 in Q2 2024, with the low at -$81147.0 in Q2 2023.
• Historically, Restructuring Costs has averaged $19368.3 across 3 years, with a median of $19289.0 in 2023.
• Annual changes were most pronounced in 2023 — Restructuring Costs tumbled 76.99% — and 2024, when it soared 229.36%.
• InMed Pharmaceuticals' Restructuring Costs stood at $44042.0 in 2022, then plunged by 76.99% to $10136.0 in 2023, then surged by 935.61% to $104969.0 in 2024.
• The last three Restructuring Costs figures came in at $104969.0 (Q2 2024), $9768.0 (Q1 2024), and $10136.0 (Q4 2023), per Business Quant data.